• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

小细胞肺癌的治疗选择——我们有更多选择吗？

Treatment options for small cell lung cancer - do we have more choice?

机构信息

Department of Medicine, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.

出版信息

Br J Cancer. 2010 Feb 16;102(4):629-38. doi: 10.1038/sj.bjc.6605527. Epub 2010 Jan 26.

DOI:10.1038/sj.bjc.6605527
PMID:20104223
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2837580/
Abstract

Small cell lung cancer (SCLC) is a significant health problem worldwide because of its high propensity for relapse. This review discusses existing and future therapies for the treatment of SCLC.

摘要

小细胞肺癌（SCLC）是一个严重的全球健康问题，因为它具有很高的复发倾向。本文讨论了目前和未来用于治疗 SCLC 的疗法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcb1/2837580/31e458ca20d7/6605527f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcb1/2837580/31e458ca20d7/6605527f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcb1/2837580/31e458ca20d7/6605527f1.jpg

相似文献

1
Treatment options for small cell lung cancer - do we have more choice?小细胞肺癌的治疗选择——我们有更多选择吗？
Br J Cancer. 2010 Feb 16;102(4):629-38. doi: 10.1038/sj.bjc.6605527. Epub 2010 Jan 26.
2
Small cell lung cancer.小细胞肺癌
J Natl Compr Canc Netw. 2011 Oct;9(10):1086-113. doi: 10.6004/jnccn.2011.0092.
3
Treatment of extensive-stage small cell lung carcinoma: current status and future prospects.广泛期小细胞肺癌的治疗：现状与展望。
Eur Respir J. 2010 Jan;35(1):202-15. doi: 10.1183/09031936.00105009.
4
Lung Cancer OncoGuia.肺癌诊疗指南
Clin Transl Oncol. 2009 Dec;11(12):805-24. doi: 10.1007/s12094-009-0449-0.
5
[Recent Advances and Future Strategies for Small Cell Lung Cancer].[小细胞肺癌的最新进展与未来策略]
Zhongguo Fei Ai Za Zhi. 2017 Jun 20;20(6):421-426. doi: 10.3779/j.issn.1009-3419.2017.06.09.
6
Managing Patients With Relapsed Small-Cell Lung Cancer.管理复发性小细胞肺癌患者。
J Oncol Pract. 2018 Jun;14(6):359-366. doi: 10.1200/JOP.18.00204.
7
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.小细胞肺癌：欧洲肿瘤内科学会临床实践指南之诊断、治疗及随访
Ann Oncol. 2010 May;21 Suppl 5:v120-5. doi: 10.1093/annonc/mdq172.
8
Origins, genetic landscape, and emerging therapies of small cell lung cancer.小细胞肺癌的起源、基因图谱及新兴疗法
Genes Dev. 2015 Jul 15;29(14):1447-62. doi: 10.1101/gad.263145.115.
9
Small Cell Lung Cancer: Advances in Diagnosis and Management.小细胞肺癌：诊断与管理的新进展。
Semin Respir Crit Care Med. 2020 Jun;41(3):435-446. doi: 10.1055/s-0039-1700566. Epub 2020 May 25.
10
Small cell lung cancer.小细胞肺癌。
J Natl Compr Canc Netw. 2013 Jan 1;11(1):78-98. doi: 10.6004/jnccn.2013.0011.

引用本文的文献

1
Machine learning-based prediction model for brain metastasis in patients with extensive-stage small cell lung cancer.基于机器学习的广泛期小细胞肺癌脑转移预测模型。
Sci Rep. 2024 Nov 20;14(1):28790. doi: 10.1038/s41598-024-80425-y.
2
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer.肺癌中 PD-1/PD-L1 和 CTLA-4 的双重阻断免疫疗法。
J Hematol Oncol. 2024 Jul 27;17(1):54. doi: 10.1186/s13045-024-01581-2.
3
Inhalable metal-organic framework-mediated cuproptosis combined with PD-L1 checkpoint blockade for lung metastasis synergistic immunotherapy.

本文引用的文献

1
Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.CONVERT试验方案——同步每日一次与每日两次放疗：一项针对局限期小细胞肺癌（LS-SCLC）且体能状态良好患者的同步放化疗国际双臂随机对照试验，比较每日两次与每日一次放疗方案
BMJ Open. 2016 Jan 20;6(1):e009849. doi: 10.1136/bmjopen-2015-009849.
2
Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.顺铂、伊立替康和贝伐珠单抗联合治疗未经治疗的广泛期小细胞肺癌：CALGB 30306，一项 II 期研究。
J Clin Oncol. 2011 Nov 20;29(33):4436-41. doi: 10.1200/JCO.2011.35.6923. Epub 2011 Oct 3.
3
可吸入金属有机框架介导的铜死亡联合程序性死亡受体1配体（PD-L1）检查点阻断用于肺转移协同免疫治疗
Acta Pharm Sin B. 2024 May;14(5):2281-2297. doi: 10.1016/j.apsb.2024.01.017. Epub 2024 Feb 6.
4
Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer.广泛期小细胞肺癌患者免疫组化常规神经内分泌标志物模式与免疫检查点抑制剂疗效的关系。
Thorac Cancer. 2024 Feb;15(6):477-485. doi: 10.1111/1759-7714.15218. Epub 2024 Jan 19.
5
Non-Coding RNAs as Key Regulators in Lung Cancer.非编码 RNA 作为肺癌的关键调控因子。
Int J Mol Sci. 2023 Dec 31;25(1):560. doi: 10.3390/ijms25010560.
6
Rare Combined Small Cell Lung Carcinoma and Lung Squamous Cell Carcinoma Response to PD-1 Inhibitor as Third-Line Therapy: A Case Report.罕见的小细胞肺癌与肺鳞状细胞癌联合病例对PD-1抑制剂作为三线治疗的反应：一例报告
Cancer Manag Res. 2023 Feb 22;15:197-201. doi: 10.2147/CMAR.S397711. eCollection 2023.
7
LncRNA H19 Promotes Lung Adenocarcinoma Progression via Binding to Mutant p53 R175H.长链非编码RNA H19通过与突变型p53 R175H结合促进肺腺癌进展。
Cancers (Basel). 2022 Sep 16;14(18):4486. doi: 10.3390/cancers14184486.
8
Gastroesophageal reflux disease and paraneoplastic neurological syndrome associated with long-term survival in limited stage small-cell lung cancer.胃食管反流病和副肿瘤性神经系统综合征与局限期小细胞肺癌的长期生存相关。
Thorac Cancer. 2022 Apr;13(7):925-933. doi: 10.1111/1759-7714.14318. Epub 2022 Feb 23.
9
Rearrangement in Small-Cell Lung Cancer and Durable Response to Alectinib: A Case Report.小细胞肺癌的重排及对阿来替尼的持久反应：一例报告
Onco Targets Ther. 2021 Oct 24;14:5161-5166. doi: 10.2147/OTT.S323700. eCollection 2021.
10
Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer.外周血指标预测安罗替尼作为晚期小细胞肺癌后续治疗的 PFS/OS。
Cancer Biol Med. 2021 Jul 24;19(8):1249-58. doi: 10.20892/j.issn.2095-3941.2020.0727.
Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group.紫杉醇联合贝伐珠单抗治疗化疗敏感复发性小细胞肺癌患者的安全性、可行性和疗效研究：印第安纳肿瘤学组的研究。
J Thorac Oncol. 2010 Dec;5(12):2008-11. doi: 10.1097/JTO.0b013e3181f77b6e.
4
Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.伊立替康和顺铂治疗后 c-Kit 阳性广泛期小细胞肺癌患者的伊马替尼维持治疗的 II 期临床试验。
Clin Lung Cancer. 2010 Jul 1;11(4):223-7. doi: 10.3816/CLC.2010.n.028.
5
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.顺铂联合依托泊苷及贝伐单抗治疗既往未治疗的广泛期小细胞肺癌的II期研究：东部肿瘤协作组E3501研究
J Clin Oncol. 2009 Dec 10;27(35):6006-11. doi: 10.1200/JCO.2009.23.7545. Epub 2009 Oct 13.
6
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.培美曲塞联合卡铂与依托泊苷联合卡铂用于初治广泛期小细胞肺癌患者化疗的Ⅲ期研究
J Clin Oncol. 2009 Oct 1;27(28):4787-92. doi: 10.1200/JCO.2009.23.1548. Epub 2009 Aug 31.
7
Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.沙利度胺联合化疗用于小细胞肺癌的抗血管生成治疗：一项随机、双盲、安慰剂对照试验
J Natl Cancer Inst. 2009 Aug 5;101(15):1049-57. doi: 10.1093/jnci/djp200. Epub 2009 Jul 16.
8
The new lung cancer staging system.新的肺癌分期系统。
Chest. 2009 Jul;136(1):260-271. doi: 10.1378/chest.08-0978.
9
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.日本-美国关于紫杉醇联合卡铂治疗晚期非小细胞肺癌的共同对照分析：一种评估群体相关药物基因组学的模型
J Clin Oncol. 2009 Jul 20;27(21):3540-6. doi: 10.1200/JCO.2008.20.8793. Epub 2009 May 26.
10
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.伊立替康/顺铂与依托泊苷/顺铂治疗广泛期小细胞肺癌的III期试验：SWOG S0124的临床和药物基因组学结果
J Clin Oncol. 2009 May 20;27(15):2530-5. doi: 10.1200/JCO.2008.20.1061. Epub 2009 Apr 6.